Login to Your Account



Jiangsu Hengrui heads West to grow innovative pipeline via $100M JV

By Shannon Ellis
Staff Writer

Wednesday, June 29, 2016

SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd. is one of China's most profitable non-state-run pharmaceutical firms focused on generics. With a market cap of $14.2 billion, last year Jiangsu Hengrui raked in revenues of $1.4 billion with a net profit of $327 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription